In Europe, two divergent paths are emerging as countries grapple with what to do about drug prices, affecting both pharma and patients — and testing the influence of the U.S.
STAT+: The shortage of many medicines in the U.S. remains a ‘systemic’ problem, a new analysis finds
The number of prescription drug shortages in the U.S. fell by 23% last year, but a new analysis found other troubling signs about medicines in short supply.
GSK is buying Nuvalent, the maker of targeted cancer drugs, for $10.6 billion, a sizable addition to the latest run of biopharma acquisitions.
AstraZeneca’s GLP-1 pill showed promise in mid-stage obesity and diabetes studies, but it may still be too early to determine how it stacks up against other oral treatments.
Johnson & Johnson said it will purchase the startup Firefly Bio for $1 billion in an effort to expand its work in the suddenly buzzy field of KRAS inhibitors.
A combination of pancreatic cancer drugs from Tango Therapeutics and Revolution Medicines led to a strong response rate in an early-stage trial.
You're reading the web edition of STAT's ADA in 30 Seconds, from the American Diabetes Association's annual conference.
Boehringer Ingelheim’s obesity drug showed promise in cutting liver fat, but it was less impressive at overall weight loss, new data shows.
Eli Lilly presented new safety and tolerability data on retatrutide at the annual meeting of the American Diabetes Association on Saturday.
Detailed data from a midstage study offered further evidence that the obesity drug Pfizer acquired from the biotech Metsera could be dosed monthly.
From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.
The White House has used the program to reward companies that help its political goals.
Otsuka’s Voyxact slowed the loss of kidney function after one year in patients with a chronic autoimmune kidney disease, but the benefit was less than expected.
The Supreme Court unanimously ruled that Hikma Pharmaceutical did not infringe patents held by Amarin in a decision with implications for lawsuits over so-called skinny labels.
For pancreatic cancer patients, the surge in interest for an exciting new drug is leaving them fearful about when they might get the treatment or if there will be enough…
New medicines are getting better. But so is our ability to get them where they need to go.
The post Revolutions in Drug Delivery first appeared on Science-Based Medicine.
New medicines are getting better. But so is our ability to get them where they need to go.
The post Revolutions in Drug Delivery first appeared on Science-Based Medicine.
Alnylam announced a three-year deal with Inceptive, worth up to $2 billion, with $30 million up front in cash and equity in the startup.
Christopher Lieu, University of Colorado Anschutz/ The Conversation
Continue Reading
Category: Cancer, Illnesses and conditions, Body and Mind
Tags: Pancreatic cancer, Drugs, Pancreas, Pharmaceuticals
Longevity startup NewLimit plans to launch its first clinical trial of a liver medicine after raising a staggering $435 million in new funding.
Eli Lilly has told more than 1,000 hospitals participating in the 340B drug discount program to submit claims data over the next five days — or lose price breaks.
Abivax said its experimental treatment for ulcerative colitis showed significant efficacy in a closely watched trial, but shares of the company tanked on safety concerns.
Here is some of what you may have missed from the world's largest cancer research meeting.
The French pharma firm Servier is buying an experimental muscular dystrophy drug from Edgewise Therapeutics for $1.55 billion upfront.
Older adults on Medicare can get Wegovy and Zepbound for $50 a month, starting in July. But the agency still is not sharing how much this will cost taxpayers.
ASCO Day 3: A huge advance for pancreatic cancer, a let down for Akeso and Summit, and a new approach to immunotherapy.
Low-dose, low-cost immunotherapies may help patients in poorer countries access high-tech cancer treatments.
By doing hormone therapy up front in prostate cancer cases, the hope was to shrink the relapse rate after surgery. Results were encouraging.
ASCO, Day 2: promising news around lung cancer, new immunotherapies, and bold words from Rick Pazdur.
CEO Mark Goldsmith says Revolution Medicines will submit pancreatic cancer drug daraxonrasib for FDA approval soon.
Page 1
Older →